Fc-Fusion Proteins also called as Fc chimeric proteins or Fc-Ig based chimeric fusion protein and also Fc-tag protein. The Fc-Fusion Protein is a composition Fc domain of IgG which is genetically linked to a peptide/protein of interest. Fc-Fusion Protein has gained importance in the in vivo and in-vitro research. The Fc-fusion proteins can range single peptides, a ligand activating upon binding to a cell receptor, signaling molecules, an extracellular domain of the receptor and also as a bait protein which identifies the binding partners in a protein microarray.
One of the important features of the Fc-Fusion Proteins in vivo is that it can prolong the plasma half-life of the desired protein. This feature of the Fc-Fusion Protein improves the therapeutic efficacy of the biological drugs. Fc-Fusion Proteins are now routinely used in the non-clinical applications like immunohistochemistry, protein arrays, and flow cytometry.In these applications, the FC region is stable and folds independently to which other different types of proteins can get attached and remain functional.
Get Sample Copy of this Report @ https://www.persistencemarketresearch.com/samples/16414
Market Segmentation:
On the basis of Application
- In vitro
- Immunohistochemistry
- Flow Cytometry
- Binding assays
- Microarray technologies
- In vivo
- Bio-therapeutic Drugs
On the basis of End-Users
- Hospitals and ASCs
- Ophthalmic or oculoplastic clinics
On the basis of Region
- North America
- Europe
- Asia Pacific
- Latin America
- Middle East & Africa
For the entire list of market players, request for Table of Content here @ https://www.persistencemarketresearch.com/toc/16414
There are many Fc-fusion proteins in clinical trials, and many are there at different stages of pre-clinical development.Fc-Fusion proteins and monoclonal antibodies collectively account for a total of 43% among the all therapeutic proteins market. Many Fc-Fusion proteins are still in pipeline which indicates that the market of Fc-Fusion Proteins is likely to rise in the forecast period 2016-2024.
From studies and global sales, the most successful Fc-fusion protein is Etanercept, which exceeded the utmost successful therapeutic antibody Bevacizumab. The market for Fc-fusion protein market is analogous to the biologics, pharmaceuticals and biotechnology market.
From the global perspective, North America accounts for the largest market share for Fc-fusion protein owing to the rising efficacy of Fc-fusion proteins therapy and adoption rate of advance Fc-fusion proteins. The high adoption rate of Fc-fusion proteins in North America probably will help the region to retain the position of the leading region in the forecast years.
Pre-Book Right Now for Exclusive Analyst Support @ https://www.persistencemarketresearch.com/checkout/16414
Currently, the global Fc-fusion proteins market is highly competitive owing to the involvement of many established players. Some of the key players in the global Fc-fusion proteins market are Astellas Pharma US, Regeneron, Amgen, Ligand Pharmaceuticals, Bristol-Myers Squibb, Viventia and Genzyme.
About Us:
Persistence Market Research is here to provide companies a one-stop solution with regards to bettering customer experience. It does engage in gathering appropriate feedback after getting through personalized customer interactions for adding value to customers’ experience by acting as the “missing” link between “customer relationships” and “business outcomes’. The best possible returns are assured therein.
Contact Us:
Persistence Market Research
Address – 305 Broadway, 7th Floor, New York City, NY 10007 United States
U.S. Ph. – +1-646-568-7751
USA-Canada Toll-free – +1 800-961-0353
Sales – sales@persistencemarketresearch.com
Website – https://www.persistencemarketresearch.com